GENETIC ASPECTS OF BETA1-BLOCKERS TREATMENT FOR PATIENTS WITH HYPERTENSIONJournal: Journal of Clinical and Experimental Medical Research(JC&EMR) (Vol.2, No. 2)
Publication Date: 2014-07-05
Authors : Dudchenko I. O.; Prystupa L. N.;
Page : 246-255
Keywords : β1-blockers; gene polymorphism; heart rate; blood pressure.;
Introduction. Analysis of scientific studies has revealed the relationship between the T393C polymorphism of GNAS1 gene and Arg389Gly of ADRβ1 gene, and effectiveness of treatment using β1-blockers. However, these results are controversial, which may be due to ethnicity of the studied groups. In Ukraine, the study of T393C polymorphism of GNAS1 gene and its impact on the effectiveness of antihypertensive therapy using β1-blockers were not carried out. Our aim was to determine the impact T393C polymorphisms of gene GNAS1 and Arg389Gly of ADRβ1 gene on efficiency of treatment using β1-blockers for patients with hypertension. Materials and methods. The study involved 70 patients with verified diagnosis of hypertension. At baseline, β1?blockers were appointed for patients at doses: metoprolol ? 12.5 mg/kg per day, carvedilol ? 25 mg/kg per day, and bisoprolol ? 5 mg/kg per day. Efficacy of treatment was determined after 2 weeks by measuring heart rate and blood pressure. Polymorphism of gene was determined by polymerase chain reaction followed by restriction fragment analysis. Statistical analysis of the data was performed using the SPSS Statistics 21.0 program. Discussion. It is proved that determining of T393C polymorphisms of GNAS1 gene and Arg389Gly of ADRβ1 gene plays an important role for the treatment with β1-blockers, because: in patients with T393T genotype of GNAS1 gene observed higher level of reduction of systolic blood pressure and heart rate, when the treatment by β1-blocker was used, than in patients with C393C genotype; in patients with Arg389Arg and Arg389Gly genotypes of ADRβ1 gene the level of reduction of heart rate and systolic blood pressure, when the treatment by β1?blocker was used, was higher than in patients with Gly389Gly genotype. in case when T393C or C393C genotypes of GNAS1 gene and Gly389Gly of ADRβ1 gene are combined, application of β1-adrenergic blockers is ineffective, even with its dose adjustment.
Other Latest Articles
Last modified: 2014-07-08 18:30:59